Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788319 | 0.95 | MAPKAPK2 (0.40) | MAPKAPK2XDHGSTP1PRMT5WDR5 | |
| SCHEMBL6792722 | 0.89 | MAPKAPK2 (0.44) | MAPKAPK2LCK | |
| SCHEMBL6794024 | 0.88 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL4264409 | 0.85 | MAPKAPK2 (0.56) | MAPKAPK2 | |
| SCHEMBL4260865 | 0.82 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL4260268 | 0.82 | HTR2B (0.43) | MAPKAPK2MAOB | |
| SCHEMBL4444521 | 0.80 | MAPKAPK2 (0.55) | MAPKAPK2 | |
| SCHEMBL4270927 | 0.80 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL1660776 | 0.80 | MAPKAPK2 (0.43) | MAPKAPK2 | |
| SCHEMBL4265876 | 0.80 | MAPKAPK2 (0.41) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885XDH 2338/4885GSTP1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.